The stock of Applied Dna Sciences Inc (APDN) has seen a -24.08% decrease in the past week, with a -15.12% drop in the past month, and a -42.06% decrease in the past quarter. The volatility ratio for the week is 10.91%, and the volatility levels for the past 30 days are at 20.51% for APDN. The simple moving average for the last 20 days is -8.95% for APDN’s stock, with a simple moving average of -87.84% for the last 200 days.
Is It Worth Investing in Applied Dna Sciences Inc (NASDAQ: APDN) Right Now?
Additionally, the 36-month beta value for APDN is 0.38. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for APDN is 55.17M and currently, short sellers hold a 9.11% ratio of that float. The average trading volume of APDN on January 15, 2025 was 6.20M shares.
APDN) stock’s latest price update
The stock price of Applied Dna Sciences Inc (NASDAQ: APDN) has dropped by -5.64 compared to previous close of 0.19. Despite this, the company has seen a fall of -24.08% in its stock price over the last five trading days. accesswire.com reported 2025-01-10 that – Signals Start of New Commercialization Phase for LineaRx Subsidiary – – Company Negotiating GMP Supply Agreement – – Company Reaffirms Strategic Restructuring Timeline – STONY BROOK, NY / ACCESSWIRE / January 10, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility (the “facility”) within its Stony Brook, New York, headquarters and readiness to accept orders for the manufacture of LineaDNA™ IVT templates that clients can utilize for the production of mRNA clinical trial materials. The facility is undergoing final testing and is expected to be fully operational by the end of the current month.
Analysts’ Opinion of APDN
Many brokerage firms have already submitted their reports for APDN stocks, with ROTH Capital repeating the rating for APDN by listing it as a “Buy.” The predicted price for APDN in the upcoming period, according to ROTH Capital is $24 based on the research report published on February 12, 2021 of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see APDN reach a price target of $14, previously predicting the price at $18. The rating they have provided for APDN stocks is “Buy” according to the report published on January 14th, 2021.
H.C. Wainwright gave a rating of “Buy” to APDN, setting the target price at $12 in the report published on December 18th of the previous year.
APDN Trading at -2.37% from the 50-Day Moving Average
After a stumble in the market that brought APDN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.73% of loss for the given period.
Volatility was left at 20.51%, however, over the last 30 days, the volatility rate increased by 10.91%, as shares sank -18.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.18% lower at present.
During the last 5 trading sessions, APDN fell by -24.08%, which changed the moving average for the period of 200-days by -97.87% in comparison to the 20-day moving average, which settled at $0.2004. In addition, Applied Dna Sciences Inc saw -10.54% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for APDN
Current profitability levels for the company are sitting at:
- -4.09 for the present operating margin
- 0.24 for the gross margin
The net margin for Applied Dna Sciences Inc stands at -2.06. The total capital return value is set at -1.35. Equity return is now at value -99.23, with -52.89 for asset returns.
Based on Applied Dna Sciences Inc (APDN), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -18.55.
Currently, EBITDA for the company is -14.02 million with net debt to EBITDA at 0.43. When we switch over and look at the enterprise to sales, we see a ratio of 1.12. The receivables turnover for the company is 9.48for trailing twelve months and the total asset turnover is 0.27. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.36.
Conclusion
In conclusion, Applied Dna Sciences Inc (APDN) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
